Brett Houk Selected Research

2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- one

12/2017	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
7/2016	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brett Houk Research Topics

Disease

3	Neoplasms (Cancer) 12/2017 - 10/2015
3	Fatigue 07/2016 - 03/2010
2	Endometrial Neoplasms (Endometrial Cancer) 12/2017 - 07/2016
2	Hand-Foot Syndrome 12/2010 - 03/2010
2	Renal Cell Carcinoma (Grawitz Tumor) 12/2010 - 03/2010
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 12/2017
1	Colorectal Neoplasms (Colorectal Cancer) 12/2017
1	Vomiting 07/2016
1	Diarrhea 07/2016
1	Inflammation (Inflammations) 07/2016
1	Nausea 07/2016
1	Pneumonia (Pneumonitis) 07/2016
1	Dysgeusia (Parageusia) 07/2016
1	Hypertension (High Blood Pressure) 03/2010

Drug/Important Bio-Agent (IBA)

2	gedatolisibIBA 12/2017 - 07/2016
2	2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA 12/2017 - 07/2016
2	Sunitinib (Sutent)FDA Link 12/2010 - 03/2010
2	Lipase (Acid Lipase)FDA Link 12/2010 - 03/2010
1	lorlatinibIBA 01/2021
1	alectinibIBA 01/2021
1	ceritinibIBA 01/2021
1	CrizotinibIBA 01/2021
1	Anaplastic Lymphoma KinaseIBA 01/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021
1	MTOR InhibitorsIBA 12/2017
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2017
1	mirdametinibIBA 12/2017
1	Irinotecan (Camptosar)FDA LinkGeneric 12/2017
1	PlatinumIBA 07/2016
1	StathminIBA 07/2016
1	Focal Adhesion Protein-Tyrosine KinasesIBA 10/2015
1	defactinibIBA 10/2015
1	CytokinesIBA 12/2010

Therapy/Procedure

1	Therapeutics 01/2021
1	Intravenous Infusions 07/2016
1	Drug Therapy (Chemotherapy) 07/2016